Evaxion, ExpreS2ion Ink Research Pact For Cytomegalovirus Vaccine Candidate

 

• Evaxion Biotech A/S 
  EVAX+ Free Alerts
   has signed a Vaccine Discovery Collaboration Agreement with ExpreS2ion Biotech Holding AB for the joint development of a novel cytomegalovirus (CMV) vaccine candidate.
• During the discovery phase of the collaboration, Evaxion will use its proprietary AI platform, RAVEN, to design a next-generation vaccine candidate that elicits both cellular and humoral/antibody responses. 
• The antigen constructs derived from Evaxion's AI platform will be produced by ExpreS2ion, followed by assessments in Evaxion's preclinical models. 
• The joint discovery project will be included in Evaxion's development pipeline under EVX-V1.
• Under the terms of the collaboration, ExpreS2ion will have the exclusive right to license the CMV vaccine candidate. The research and intellectual property licensing costs will be divided 50/50 between the parties until 2025.
• A potential future Development and Commercialization Agreement for the jointly discovered CMV vaccine candidate is expected to include an upfront payment and future milestone payments to Evaxion from ExpreS2ion not exceeding a six-digit USD amount, as well as sub-licensing royalty.

https://www.benzinga.com/general/biotech/22/12/29972794/evaxion-expres2ion-ink-research-pact-for-cytomegalovirus-vaccine-candidate